Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells.

Mechanism / theoretical grounding — not clinical validation.

Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. Biochemistry (Mosc). 2015.

Organ: liver-metabolic · Type: in-vitro · Peptides: Pancragen, Bronchogen

In aging pancreatic and bronchial epithelial cultures, KEDW and AEDL tissue-specifically tracked promoter methylation and expression of selected transcription-factor genes — culture epigenetics, not a clinical study.

Editorial summary of a 2015 original article in Biochemistry (Moscow). Aging human epithelial cultures. Public pages cite PubMed only. Read the paper: PMID 25761685.

Methods

Pancreatic and bronchial epithelium cell cultures were aged in vitro. The authors measured expression of genes encoding transcription factors and other proteins, promoter methylation of named loci, and tissue-specific peptide treatments: KEDW (Pancragen) on pancreatic cultures and AEDL (Bronchogen) on bronchial cultures. Loci include PDX1, PAX6, NGN3, PAX4, and FOXA2 in pancreas, and NKX2-1, SCGB1A1, FOXA1, SCGB3A2, SFTPA1, and FOXA2 in bronchus. Passage numbers and peptide concentrations belong in the primary text.

Findings

This paper is mechanistic or modeling evidence, not a clinical trial. Expression of several genes changed with culture aging. Promoter methylation of PDX1, PAX6, and NGN3 in pancreatic cells and of NKX2-1 and SCGB1A1 in bronchial cells changed with aging in correlation with expression, and the authors treat those methylation shifts as a possible cause of age- and peptide-linked expression change. PAX4 (pancreas) and FOXA1, SCGB3A2, and SFTPA1 (bronchus) changed in expression without methylation change and were unaffected by the peptides at those promoters. FOXA2 methylation in pancreas did not correlate with expression; the FOXA2 promoter was fully unmethylated in bronchial cells regardless of age or AEDL.

This is tissue-matched culture epigenetics (pancreas versus bronchus). It is not a metabolic or pulmonary trial. Follow the PMID.